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STATE-OF-THE-ART PAPERPSTATE-OF-THE-ART PAPER693Chronic MR and AR: Have Indications for Surgery Changed?Robert O. Bonow
The timing of surgery in patients with chronic mitral regurgitation (MR) and aortic
regurgitation (AR) continues to elicit uncertainty and considerable controversy. Some
patients will incur myocardial structural changes, irreversible pulmonary hypertension or
arrhythmias before they manifest other symptoms. With improvement in surgical
technique and outcomes, mitral repair can be done with low surgical risk and with
excellent long-term durability. In AR, decision making is more complex as patients
almost invariably require valve replacement. Prospective clinical trials are needed to
determine the optimal timing of surgery, including the use of biomarkers and new
methods to assess interstitial fibrosis and regional myocardial function.CLINICAL RESEARCH CORONARY ARTERY DISEASE
702resence or Absence of Angina Not Associated With Mortality or
Cardiovascular Outcomes in Patients With Type 2 Diabetes and Stable CADGilles R. Dagenais, Jiang Lu, David P. Faxon, Peter Bogaty, Dale Adler, Francisco Fuentes, Jorge Escobedo,
Ashok Krishnaswami, James Slater, Robert L. Frye, and the BARI 2D Study Group
It is unclear whether in patients with type 2 diabetes and stable coronary artery disease
(CAD) the risk of all-cause mortality and cardiovascular events varies according to the
presence or absence of angina. Dagenais and colleagues performed a post-hoc analysis of this
type of patient enrolled in the BARI 2D (Bypass Angioplasty Revascularization Investigation
2 Diabetes) trial. During 5 years of follow-up, there was no difference in cumulative death
rates or in the rates of the cardiovascular composite outcomes between patients with no
symptoms, those with angina, and those with anginal equivalent symptoms at baseline. These
findings suggest these patients should be similarly managed in terms of risk stratification and
preventive therapies.
Editorial Comment: Peter H. Stone, p. 712(continued on page A-28)
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714ental Stress Induced Myocardial Ischemia
May Be More Common Than Exercise-Induced IschemiaWei Jiang, Zainab Samad, Stephen Boyle, Richard C. Becker, Redford Williams, Cynthia Kuhn,
Thomas L. Ortel, Joseph Rogers, Maragatha Kuchibhatla, Christopher O’Connor, Eric J. Velazquez
Jiang and colleagues evaluated the prevalence of mental stress–induced myocardial ischemia.
Patients with clinically stable coronary heart disease underwent a battery of 3 mental stress
tests followed by a treadmill test. Ischemia, was assessed by echocardiography and
electrocardiogram. Mental stress–induced ischemia occurred in 43%, while exercise-induced
ischemia occurred in 34%. Females (odds ratio [OR]: 1.88), patients who were not married
(OR: 1.99), and patients who lived alone (OR: 2.24) were more likely to have mental
stress–induced ischemia. Mental stress–induced ischemia may be more common than
exercise-induced ischemia.CORONARY ARTERY DISEASE
723icagrelor Enhances Adenosine-Induced
Coronary Vasodilatory Responses in HumansAnn Wittfeldt, Håkan Emanuelsson, Gunnar Brandrup-Wognsen, J. J. J. van Giezen, Jenny Jonasson,
Sven Nylander, Li-Ming Gan
Wittfeldt and colleagues sought to determine if ticagrelor augments adenosine-induced
coronary blood flow and the sensation of dyspnea. In this double-blind, placebo-controlled
study, healthy subjects were randomized to receive a single dose of ticagrelor or placebo, in a
crossover fashion. Coronary blood flow velocity (CBFV) was measured by transthoracic
Doppler echocardiography of the left anterior descending artery. Ticagrelor significantly
increased the area under the curve of adenosine-induced CBFV, an effect that was
significantly attenuated by theophylline. Similarly, ticagrelor increased the sensation of
dyspnea during adenosine infusion. These results show that ticagrelor enhances
adenosine-induced CBFV and dyspnea via an adenosine-mediated mechanism.(continued on page A-29)
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728olymorphism in Haptoglobin Gene May Explain
Much of the Increased Risk of CVD in DiabeticsLeah E. Cahill, Andrew P. Levy, Stephanie E. Chiuve, Majken K. Jensen, Hong Wang, Nawar M. Shara,
Shany Blum, Barbara V. Howard, Jennifer K. Pai, Kenneth J. Mukamal, Kathryn M. Rexrode,
Eric B. Rimm
Compared to the Haptoglobin (Hp)1-1 genotype, individuals with the Hp2-2 genotype
produce a protein that is dysfunctional in protecting against hemoglobin-driven oxidative
damage. Glycosolation of hemoglobin may further interfere with the activity of Hp2-2
protein. Cahill and colleagues determine glycosylated hemoglobin (HbA1c) concentration and
p genotype in a case-control cohort from the Nurses’ Health Study, and in a replication
ohort of 2,070 individuals, and then also combined with data from the Strong Heart Study.
n a pooled analysis, participants with both the Hp2-2 genotype and elevated HbA1c
6.5%) had a relative risk of 7.90 for coronary heart disease (CHD) compared to
articipants with both an Hp1 allele and HbA1c 6.5%, while the Hp2-2 genotype with
bA1c 6.5% did not increase risk. These findings may help explain inconsistencies in the
literature for the association of glycemic control with cardiovascular disease outcomes, as well
as inconsistencies in prior studies of Hp genotype and CHD.Editorial Comment: Robert Roberts, p. 738HEART RHYTHM DISORDERS
741o Difference in Outcomes Between Successful or
Failed Strict Rate Control for Patients With Atrial FibrillationHessel F. Groenveld, Jan G. P. Tijssen, Harry J. G. M. Crijns, Maarten P. Van den Berg, Hans L. Hillege,
Marco Alings, Dirk J. Van Veldhuisen, Isabelle C. Van Gelder, for the RACE II Investigators
The RACE II study (Rate Control Efficacy in Permanent Atrial Fibrillation) showed no
difference in outcomes between lenient and strict rate control in patients with permanent
atrial fibrillation. However, not all patients achieved the target heart rate in the strict rate
control arm. Groenveld and colleagues investigated whether there were differences in
outcomes between patients treated with successful strict, failed strict, and lenient rate control.
The heart rates were significantly different after the dose-adjustment phase between the
successful strict (72 beats/min), failed strict (86 beats/min), and lenient (93 beats/min) groups,
and remained significantly different during follow-up. There were however, no differences in
the primary outcome, or in measures of quality of life.
Editorial Comment: Rod Passman, p. 749(continued on page A-30)
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752poB/ApoA-I Ratio Is Associated With
Increased Risk of Bioprosthetic Valve DegenerationHaïfa Mahjoub, Patrick Mathieu, Mario Sénéchal, Eric Larose, Jean Dumesnil, Jean-Pierre Després,
Philippe Pibarot
This prospective study sought to identify the clinical and metabolic determinants of
bioprosthetic structural valve degeneration (SVD). A total of 203 consecutive patients with an
aortic bioprosthetic valve were recruited. SVD was defined as an increase in mean
transprosthetic gradient 10 mm Hg and/or a worsening of transprosthetic regurgitation
between 1-year post-operative echocardiography and last follow-up echocardiography. A total
of 20% of subjects developed SVD. Multivariate analysis revealed that increased
apolipoprotein B (ApoB)/apolipoprotein A-I (ApoA-I) ratio and the use of bisphosphonates
were the strongest independent predictors of SVD. This is the first study to report a strong
association between increased ApoB/ApoA-I ratio and the risk of developing SVD among
patients with aortic bioprosthetic valves.RANDOMIZED CLINICAL TRIALS
762atient- and Trial-Specific Barriers to
Participation in Cardiovascular Randomized Clinical TrialsSeth S. Martin, Fang-Shu Ou, L. Kristin Newby, Victoria Sutton, Patricia Adams, G. Michael Felker,
Tracy Y. Wang
Slow or incomplete enrollment can undermine trial completion, statistical power, and the
timely availability of results to guide clinical practice. Martin and colleagues sought to
quantitatively examine the association of patient- and trial-specific factors with participation
in cardiovascular randomized clinical trials. Screening logs from 15 cardiovascular randomized
clinical trials at a large academic medical institution were reviewed. A total of 42% of patients
did not participate in a trial. Intensive trial-related testing and anticipated trial participation
6 months were trial-specific factors associated with low enrollment. Patient-specific factors
included older age, out-of-state residence, and female sex. Race was not associated with
participation. The authors postulate that innovative trial designs fostering convenience may
enhance trial participation.Editorial Comment: Robert L. Frye, p. 770YEAR IN CARDIOLOGY SERIES YEAR IN CARDIOLOGY SERIES772Year in ElectrophysiologyGregory M. Marcus, Edmund Keung, Melvin M. Scheinman
Marcus and colleagues review articles that were published last year in the field of cardiac
electrophysiology that were felt to be particularly relevant to general cardiologists. Key
highlights from several articles are related and the clinical significance discussed with a
thoughtful comparison of data regarding the role of the newer anticoagulants apixaban,
dabigatran, and rivaroxaban.
